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O&e&es.Thisstudywasdunetacomparechamcteristicaand 
onteomes of patients with acute m-l Swctioa participat- 
ingintwotbrom~hIalstithtbosedmnl~ptientsat 
stndy ImspitaR and extmlal haspitals. 
lif&pfd Prefeamthd -lit of lower risk patients 
itbtoratl~hialsof~~heen~$ 
earRerszhdes.Eerpe*er,to&tetherehasnotbeenodeRnitive 
popnbition-bllsedenmpmisonof~and-for 
tllmwy&trirl~tilldoMspsrtiripmus. 
~P~~~~~~~~DS~ 
tUOrtaiagfkOtUWt&~-iilisrrtiop~1hospitrrlSiIl 
Ontariofnmt19g9to1992vfeN!RttRsdtodataantriaipaxt& 
patsinSwodistidtlawaseiysisstndies(GUSFOIdLATE), 
lttCkUW~1~pt&?EtSeaterodilltOGUSFO,l2~UOll- 
participantsatGUSTOhospitais,249paRentsemeredittts 
L4T&S$97rumpakipatttsatLATRbospRakand~ 
patientsatextenttdbospitals.Illeslaie-were- 
inage+gender,amwbi&ysco~conmaty~tiaa 
rtnd?3ldvaltQ~~ 
ResukPatientsitthathGUSTOandLATRweresigt&a@ 
mare~tabecXtyearsaId(addsmtio[OR]2.ftand3.2, 
tespedvely), to be male (OR 2.0 and 2.1, lvqeaay), to kove low 
Tine need for large simple trials has been recognized for many 
years (1). In cardiovascular mcdiiine, such trials have random- 
ized tens of thousands of patients using broad eligibility criteria 
to confirm that intravenous thrombolyuii confers a clinically 
important reduction in risk of death after acute myocardial 
infarction (2). Resii their obvious advantages of statistiil 
power and unambiguous end points, these trials 1 jve general- 
ixabihty advantages. Their simple protocob are designed to 
allow a broad range of hospitals to participate and to maxim& 
randomization rates among eligible patients at study hospitals. 
Nonetheless, patients selected for entty into large (and 
small) thromboiysis triak have had lower mortality than those 
not sclcctcd for randomiition. An ovetview of tm 
t* covering 5S$M patients showcd a short-term (30 to 35 
days) mortality of 95% (2). In collu;rst, popuMon-based 
studies in North America show that the current in-hn@al 
mortality rate from acute myowdkl infarctii is at least 1.5 
to Z-fold higher (3.4). exceeding the mortality seen among 
patients.randomixedtoreceiveplaceboornothrombolytk 
agent. 
Onlysomeofther~easonsfortkbqermortaRirate 
amongmt&mkedpatkntsareknownTodate,therehave 
been c-am+ys within study centa., but a popu&ow 
widcexminatroaoftbRsesetedioo~is~wsing 
it&r&on in on- 
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mortality observed between patients entered into two recent 
large-scale randomized trials of thrombolysis, GUSTO (5) and 
LATE (6), and nontrial patients either at the same hospital or 
at external hospitals not participating in these trials. An 
advantage of this comparison is that allowed time from symp- 
tom onset to presentation was 0 to 6 h in GUSTO versus 6 to 
24hinLATE. 
Methods 
Snmce of data: BMRI data We used computerized data 
on hospitalization for acute myocardial infarction from the 
Hospital Medical Records Institute (HMRI) for fiscal years 
(April 1 to March 31 of the next year) 1989 to 1992. By law, all 
acute care hospitals in Ontario submit an abstract for each 
hospitaI separation (diiharge~ transfer or death) to the HMRI 
in&ding date of birth, sex, major procedures (including 
coronary artery bypass grafting or percutaneous transluminal 
cororm-y angiopkrsty), secondary diagnostic codes and dates of 
admission and separation. These are coded on a standardized 
ha& by trained health record technicians using the Intema- 
tional f&.&cation of Disease, ninth version (ICD-9) system. 
We inch&d only those records where the primary discharge 
diagno& was acute myocardii infarction (ICD-9 code 410). 
Concomitant bypass grafting or coronary angiopkisty was 
determined from codes 480 to 483 under the Canadian Clas- . . sdicatton of Diagno&, Therapeutic and Surgical Procedures 
(7). &morbidity scores were assigned to patients using Deyo’s 
adaptation of Cha&nn’s comorhidity in&x (8,9), as in other 
adyses of acute myocardial infar&m (10). (The Charlson 
index [S] is additive. It gives scores of 1 to conditions such as 
chronic puhnonary disease or diabetes without end organ 
damage; 2 to moderate or severe renal disease, diabetes with 
end organ damage, or lymphoma; 3 to moderate or severe liver 
disease, and 6 to &astatic solid tumor or AIDS.) 
There were M,726 primary acute myocardial infarctions 
caded aver the above 4 fiscal years Of these, 641(0.72%) were 
excluded because the patients were older ‘than 105 years or 
younger than 20 years oId, the record had tnissii information 
on gender, or the patient signed her- or himself out of hospital. 
Of all prinwy aarte +cnrdii infarction coded patient$ only 
1415 (2.1%) underwent a bypass grafting cr coronary angio- 
@asty procedure on the index admiin either at the original 
admitting hospital or after transfer to a tertiary cenier, 3 of 
these patients were among the 641 excluded for the reasons 
I&ted above. 
Iy3k Mls. We used data from two trials of 
~~~h~~~ afthecanadiansRtdycaar- 
dinatar for both (Rot PauI W. Armstrow Edmonton AI- 
berta).TbeGIahaIudibationafsheptoLinaseandl-II 
PIadmgen Activator for Qccluded Coronary Arteries or 
GUSTO (5) compamd four thrombolytic strategies in acute 
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Assessment of Thrombolytic Efficacy or LATE (6) compared 
tissue plasminogen activator to placebo in patients of any age 
presenting 6 to 24 h after symptom onset with suspected acute 
myocardial infarction. The ECG criteria ‘included, variously, 
ST elevation, ST depression, Q waves, T wave inversion or 
equivocal ECG changes accompanied by elevation of myocar- 
dml enzymes. LATE hospitals in Ontario randomized 249 
patients from August 1989 to February 1992. 
Six of 30 GUSTO hospitals (20%) and 4 of 10 LATE 
hospitals (40%) were university centers with cardiac revascu- 
larization facilities. These university hospitals recruited 21.9% 
of the 1,304 GUSTO and 33.2% of the 211 LATE patients 
included in our study. Seven hospitals participated in both 
GUSTO and LATE. 
We retrieved the records for GUSTO and LATE patients 
from the HMRI data bases by using a computerized algorithm 
(11). This program matches on sex, date of birth, date of 
admission and residence code. Complete trial information on 
sex, date of birth and date of admission was available for 1,414 
of the 1,422 GUSTO patients and all 249 LATE patients. 
Allowing for variation in the date of admission by <l week or 
inversion of the month-day-year sequence for date of biih or 
date of admission, 1,304 of the 1,424 GUSTO patients (92.2%) 
and 211 of 249 I .A’I E patients (84.7%) could be matched to 
HMRI. 
Tmckhrg !rIaI :i;id nontrial patieats. A known source of 
double counting of AM1 patients in administrative data is 
recurrence of ICD-9 410 codes when patients are readmitted 
for complications or procedures such as angiography (1213). 
We tracked patients longitudinally to mitigate this source of 
error. The acute myocardial infarction admissions recorded in 
HMRI were categorized as trial patients based on matching to 
the trial data bases, or as nontrial patients. For nontrial 
patients, the first record chronologically was taken as the index 
adrnissii, and acute myocardial infarction admissions with 
matched identifiers that occurred within 90 days of the dii- 
charge date of the index admission were deieted as potential 
false-positive ICD-9 410s except in the extremely rare event 
that patients died after transfer or readmission. In this in- 
stance, the death was attributed to the original group (trial or 
nontrial) and admitting hospital. A similar algorithm was used 
for trial patients with one variation: because trial participation 
rather th.ut c~ronoIogy defined the index adntimii we also 
censared acute myocanhal infarctions from the nontrial data 
base if the same patient was admitted ~90 days before the 
index/trial acute myoca&al infarction admission. The effects 
of these tracking maneuvers were miniial, as numbers of 
acute myocardiil infarctkms were similarly reduced in both 
groups and very few subsequent in-hospital deaths were added 
to case fatatitii taIIied from the index admission. 
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Tahte 1. Comparison Groups Used to Evaluate Characteristics and Outcomes of Acute hlyocardial Infarction Trial Patients 
84,726 Ptimaty Ah41 from 1989 to 199.2 in HMRI data baw in Ontario 
1 
1 
32,640 Eligible by matching for time period for GUSTO and WTE trials 
1 
Matching of GUSTO (n = 1,414) and LATE (n = 249) patients to HMRI data base 
1 
30 GUSTO Hospitals 10 LATE Hospitals 
GUSTO NOlttd LATE LATE Nonirial GWTO 
Partkipann PartieipanrS overlap PtlItiCipanl~ F,uticipan& overlap 165 ELxtsmal Hospitak 
Il=l,304 o = 12,657 n = 85 (excluded) n = 211 o-5.997 ” = 87 (excluded) n=12,22 
AMI = acute myocardial infarction; GUSTO = Global Utiiiition of Streptokinase and Tissue Plasminoge~ +ztctnator for Occ’ ,ded Coronary Art.sies; LATE = 
late Asesment of Tbrombolytic Eflicwy. 
patients who signed themselves out of hospital. With GUSTO 
in-hospital mortality as the standard, the sensitivity for detec- 
tion of deaths by HMRI was 97.8% (90/92 deaths), and the 
specificity was 100% (1,211/1,211 alive). For the 211 patients 
matching to both the LATE and HMRI data bases, the LATE 
data base showed 19 in-hospital deaths and 192 patients aliie. 
The HMRI data base showed 12 deaths at the admitting 
hospital, 2 further deaths on transfer to other hospitals, 198 
patients alive and 1 patient voluntarily signed out of hospital. 
With LATE m-hospital mortality as the standard, the sensitiv- 
ity for detection of deaths by HblRI was only 73.7% (14/19 
deaths), although the specilicity was 100% (192&X? alive). The 
combined results for both GUSTO and LATE showed a 
sensitivity of 93.6% (104/111 deaths) and specificity of 100% 
(1403/1403 alive). 
Comparlsoa groups. Table 1 shows the comparison 
groups. GIJSTG patients (n = 1,304) were compared to 
nontrial patients at the same hospitals (n = 12,657) and 
external hospitals (n = 12299). LATE patients (n = 211) were 
compared to nontrial patients at the same hospital (n = 5,997) 
and externai hospitals (n = 12,299). All nontrial patients at 
either study hospitals or external hospitals were selected over 
the same time period as the conduct of the trials. As GUSTO 
and LATE hospitals overhqped, we aimed to preclude partic- 
ipants in one trial from being part of the comparison group of 
noqtrticipants for the other trial Thii exchtded 87 patients in 
GUSTG and 85 in LATE. However, there were 118 (0.93%) 
and 38 (0.63%) GUsrO and LATE participants, respe&ely, 
with remrds that were miming date of birth or sex or otherwise 
cotddnotbematched.Eachsetoftrialparticipantsmigh~ 
aocordingiy, be included ill the nonparticipant5’ ccmpmim 
group for the other trial Fortunately, these numbers were very 
smallinrelationtotheoverallsir.eoftbecompa@ngroups, 
andtheirimpgct,ifany,wouldbetobiastberesultstoward 
drdiaenacePbetweea~tsand~cs 
Continuous~weremmpared 
bytlnpaidt-tests;catqpricvariableswwecoarparedwith 
tz4MpretestsBasedon~datashowingtllatngeand 
sex are key predictors of slrvival (3,14,iS) and that’ revascu 
larization may reduce mortality after acute myocardial infarc- 
tion (15,16), we prespeciged our survival comparisons to adjust 
for these variables. As noted above, a comorbidity index was 
included because of the known impact of noncardiac diseases 
on hospital outcomes from cardiovascular conditions (8-10). 
The following groupings were used: age 0@70~ sex male or 
female, mmorbidity <l versus s 1 and mronary revascularixa- 
tion yes or no. The odds ratios (OR) were derived by the 
cross-product method with Cornfield estimates for the 95% 
m&ence limits (95%CL). Multivariate analysis was done by 
unconditional logistii regression to derive adjusted odds ratios 
(ORa) for smvival (17). &variates in the regression model 
were individual characteristics (age, sex, coronary revascular- 
ization and comorbidity) and either randomimtion into a trial 
(yes or no) or admission to a study hospital (yes or no). All p 
values reported are hvc-sided. 
RWlR!4 
mortality rate, age, sex, revasadakation rates, mmorbidity 
scores and mean length of stay for patients sutvkg to 
discbarge in the hospitals participating m’GU!XO or LATE 
The in-hospital mortality rates for GUSTO and LQE patients 
were markedly lower (6.9% and 6.6%, respectively) than for 
trial mn~partieiprmts at those ho@& (16.8% ad 19.7%; p < 
0.001 for both ctmpakm). Similarly. mortality rates for 
GUSTO and LATE patients were lower than for patients at 
external hapitak (17.4%; p < 0.001 for ho& comparisons). 
lncompmkmtononhialpatientsattheirrespectivehos- 
pitals, both GUsrO and LATE patients were s&@mmdy 
moreW;e$tobeundcrage71)(OR=28aMt3.2~ty 
Tabk3),bemale(OR=20and21,respe&ely)andhave 
low-tyscores R = 20 and 23, 
GUSlDpatkSsweR? 
coronmy revascukuiPtian(oR = 24ElzLial pi?&nk 
RSdlitSWlEtiidi3l~GUSTGand~~tTialptiefltS 
werecompamdtopatiemsatextemalhospimR(Tabk3). 
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Table 2. Mortality, Gender, Age, Rewcularizazatio:: and Length of Stay by Comparison Group 
GUSTO Hosaitak LATE Howirak 
,_.i- 
I -.'- 
characteristic 
(II = 30); (II = loi* External 
GUSTO NClIllri~l LATE Nontrial Hospitals Fibrinolytic 
Participant Patient Participant Parient (n = 165) Trials ovewkw 
Number of patiena 
9s oeatbs (n) 
I (n) deaths 
on day o-1t 
on dw 2 or more 
I.304 12,657 2ll 5.997 12,zw 58.600 
6.9 (90) 16.8(?131) 6.6 (14) 1Y.7(1181) 17.4(?137) llJ.5’~: 
53.3 (48) 35.3 (752) 7.1 (I) 3i.3 (440) 38.3 (XIR) 36.8% 
46.7 (42) 64.7 (1379) Y2.Y (13) 61.7 (741) 61.7(1:19) 63.2% 
9% (n) &gc 70 23.4 iws, 45.9 (SRIZ) x4 (43) 35.2 (2708) 47.0 (5782) >age 75: 9.11% 
Ace 6%74z29.W 
W (2) female 
% (II) bypass grafting or 
coronary angioplasty 
% (a) mmorbiiity index = 
1 or higher 
Mean days of stay 
(standard error)f: 
22.2 (289) 
4.1 (54) 
30.4 (397) 
9.1 (0.13) 
36.7 (M13) 
i.8 (225) 
17.2 (5970) 
10.2 (0.1:) 
21.33(45) 
2.8 (6) 
27.0 (57) 
9.1 (0.3-q 
36.7 (?!Ol) 
3.6 (216) 
46.3 (2779) 
Ii.4 (0.17) 
36.1 (4441) 
IS (189) 
46.9 (5766) 
10.6 (O.09) 
23.6% 
Not applicable 
Not applicable 
Not applicable 
*There were seven hospitals that panicipatcd in lulh GUSTO and LATE. Nontril patients at [hew hospital\ who overlapped with GUSTO or LATE were 
excluded (see text for details). Way 0 is the date of admissios. fFor surviviar p&nts. Abbreviations as in Table I. 
Behveen-hospital diffemces lor nootrial patients. Non- 
trial patients at-GUSTO hospitals did not differ significantly 
from patients at external hospitals in age, sex, coronaq re*:az- 
cularization rates or comorbidity scores (Table 3). Nootrial 
patients at LATE hospitais and patients at external hospitals 
did not differ significantiy iu sex, were slightly more likely to be 
Tabte 3. I)ifferenccs Among GUSTO and LATE Patients and Nontrial Patients at Sarrc Hospitals or 
at External Ho&air 
cbaraaerk1k 
GUSTO \s. Nontrial Patients 
at Same Hospitals: 
OR (95% CL)’ 
GUSTO Panicipa~ts vs. 
External Hqitak: 
OR (9% CL) 
Age <70 yr 
Yak 
Bypass phing or curonary aagiopIa%y 
Commbiiiiy index <I 
Shoner leaglh of say (day+ 
Age <70 yr 
Male 
Bypass grafting or coronq ;mgii@aq 
Comwbidity i&x C I 
Sbwter Icngth nr slay (day\)? 
2.8 (2.4-3.2) 
2.0 (1.8-2.3) 
2.4, I .7-3.3) 
2.3 (I .X-2.3) 
p = O.(KlI 
2.9 (2.5-3.3) 
2.0 (I .7-2.3) 
2.8 (2.0-3.X) 
2.0 (I .R-2.3) 
p = 0.1101 
LATE ~5. Nontrial Patien& LATE Participants m. 
at Same Hospital: External Hospitals: 
OR (955 CL) OR (95:: CL) 
3.2 (X.1-4.6) 
1.1 (LS-3.ll) 
Il.8 (0..3-1.9) 
2.3 (1.7-3.2) 
p = O.wl 
3.5 (23-4.9) 
2. I (I .5-30) 
1.9 (0.7-4.4) 
2.4 (1.X-3.2) 
p = O.(K)1 
Noraria Wcnts at GUSTO 
Hqitak vs. External 
Hospitals: 
OR (95% CL) 
Nontrial Patients ac LATE 
Hqitak K Entcmal 
HoSpit& 
OR (95% CL) 
l.O(LO-1.1) 
1.0(0.9-1.1) 
12(1.0-1.4) 
1.0(0.9-1.1) 
p = .o.wl 
1.1 (LO-1.2) 
1.0(0.9-1.1) 
2.4 (2.0-2.9) 
LO(Lo-1.1) 
p = O.Ml$ 
JACC Vol. 27. No. 6 JHAETAL. 
May 1996~1335-42 
1339 
THROMBOLWIS TRIAL OUTCOMES 
Table 4. Predictors of Survival Among GUSTQ snd LATE Patients and Nontrial Patients at Same 
Hospitals or at External Hospitals 
Characteristic 
GUSTO panicipant 
Age<myr 
Male 
Bypass grafting or coronary ““gioplasly 
Gxnorbidity index = 0 
LATE participant 
Age <70 J’ 
MdC 
FIypa gmliiig or coronary angioplasly 
Comorbidity index = 0 
GUSTO center 
LATE center 
Age <70 yl 
Male 
Bps gtaftiag or coronary angbplasty 
Gmuxbiiity index = 0 
Adjusted OR (95% CL): Adjusted OR (95% CL): 
All Patients at GUSTO Hospitals GUSTO Participants aad Eaemal 
(n = 13,961) Hospit& (n = 13,603)’ 
1.8(1.4-2.2) 1.8(15-2.4) 
2.6 (2.4-2.9) 3.4 (3.0-3.7) 
1.2(1.1-13) 1.2(1.1-1.4) 
1.3 (0.9-1.9) 1.5 (1.0-3) 
1.6(1.5-1.8) 1.8(1.6-1.9) 
All Patients a* LATE Ho@& LATE Panihpaats and Extcmai 
(n = 6,02g) Hospitals (n = I2.VO) 
2.1(1.2-3.6) 1.8(1.0-3.2) 
2.3 (2.0-2.6) 3.2 (2.9-3.6) 
l.l(l.O-1.3) 1.3 (1.1-1.4) 
1.5 (1.0-2.5 1.6 (1.0-2.7) 
1.6(1.4-1.8) 1.8(1.6-2.0) 
Nontrial Patienlr at GUT0 Nomrial Parkas at LATE 
Hospitals and -&tcmal Ho@& Hospitals and JZxtemal Hospirals 
(n = 24,956)t (a = 18.22)): 
1.0(0.9-1.1) NA 
NA 0.8 (0.8-1.0) 
3.1 (2.9-3.4) 3.1(2.6-3.4) 
l.?(Ll-13) 12(1.1-13) 
1.4 (1.0-1.9) 1.4 (LO-1.9) 
1.K (1.7-2.0) 1.8(1.6-1.9) 
‘Adjusted for age (<70 vs. ?70), sex. bvpasr graft& or u~o~ary mgiopby &s@~). mmorbidity index (0 K 21) 
and wti0a to trial a~ noted (y&0). iAdjusted fw age (cm K 270). sex. bypass gmfhg w coronary 
angioplasty (yes/M). comcxbiiity index <O vs. 2 1) and admkba IO trial bpiials as noted (y&w). NA = sot apptii; 
other abbreviations as in Tabtcs 1 xad 3. 
under age 70 (OR = l.l), but were significantly more likely to 
undergo coronary revascularization compared to patients in 
external hospitals (OR = 2.4). The higher rate of revascular- 
ization among nontrial pztients at LATE hospitals eliminated 
the revasadarization gradient (seen at GUSTO hospitals) for 
trial compared to nontrial patients at LATE hospitals. 
Predictors of suwivaL Univariate prediioa of survival to 
discharge among patients at external hospitals were age 00 
(OR = 3.7, 95%CL 3.4-4.2), male sex (OR = 1.7, 95%CL 
M-1.8), coronary revascularization (OR = 2.2, 95%CL 1.3- 
3.7) and comorbidity score <1 (OR = 2.2, %%CL 20-2.4). 
After adjustment for each other, the odds ratios for these 
factorjwere as follm: age ~70 (ORa = 3.L %%CL 29-3.6); 
male sex (ORa = 1.5 %%CL 1.1-1.4); revasfularization 
(ORa = 1.6, 95%CL l.O-2.7), and comorbii score <1 
(ORa = 1.8, 951CL 1.6-1.9). 
Table45umr~izesthe -nP=i=~amonggroupsof~ 
and nontrial patients. (Only adjusted OR.5 are showni results 
fortheunivariateana@fzsareavaiWeonrequesL)Com- 
pared to nontrial patients at GMT’0 hospit& GUSTO trial 
patients hcui a ~rvival advantage that rema&d sign&ml 
after adjustmf!nt for age, m coromq mtion and 
almohayxeore(0Ra= 
patients again had significantly better survival (ORa = 1.8 for 
both GUSTO and LATE, Table 4). 
A survival advaotage of trial participants might occur if 
nontrid patients died before they could be considered for study 
recruitment. However, GUSTO patients had more deaths on 
day 1 than did nontrial patients at GU!ZO hospitals--an 
observation compatible with the known early hazard of thmm- 
bolytictherapy.Whenwerepeatedtheanaly&resQic@itto 
personsaliionday2followingadm&oaatGUSKhospi- 
tals, GUSTO participation continued to predict sunival from 
day 2 to discharge (ORa = 26, %%CL 1.9-35). A similar 
trendatLATEhqitakdidnotreacbstatistii@Scamx 
(ORa = 1.5,9S%CL 0.9-26), probably because af the small 
numberofdeathsafterday2(n= 13)amongfAIEemdlees 
Fii,survhdinnontriaipatienkat~u~hosjhk 
eompad to patients at external hospitab was basidy iden- 
tical (ORa = I.&, Table 4). Nontrial patients a¶ IArr: 
bospita!shadamaq$nal!ysigdcantreduatiincbanaeof 
survh!;‘-.p;I=O.8)aqaredtopatienkatextedbospi- 
tak. 
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same jurisdiction and generated two key findings. First, 
GUSTO and LATE participants differ systematically in several 
respects from non-trial patients, either at GUSTO and LA= 
study hospitals or at external hospitals (Table 3). Second, even 
when these diierences were taken into account, GUSTO and 
LATE participants had nearly a twofold increased chance of 
surviving hospitalization after aLute myocardial infarction (Ta- 
ble 4). 
SelectIon of low risk patients into trials. Previous studies 
have reported that younger and male patients are more often 
selected for entry into trials of thrombolysis (18J9). We have 
proven that this selection bias arises within hospitals pattici- 
pating in trials rather than through differences in patient 
populations between hospitals that do or do not join trials. We 
have extended these findings to show lesser degrees of comor- 
bidity, shorter lengths oE stay and higher rates of revascular- 
ization among trial participants. Nontrial patients at LATF, 
hospitals also had higher revascularization rates compared tJ 
patients at external hospitals, but this probably reflects the fazt 
that 4 of the 10 LATE hospitals had on-site revascularizati~Jn 
capacity-a factor previously shown to increase use of revas- 
cularization after acute myocardial infarction in Ontario CO). 
The observed characteristics of trial patients-younger. 
more after? male, less comorbidity and more likely to undergo 
revascularL&n-are obviously linked. In general, women 
with acute myocardial infarction are older (3); older patients 
have more comorbidity; and, ceteris pa&us, worllen are less 
likely to undergo revascularization after acute myocardial 
infarctiou (21). Tbrombolysis per se has also been shown to 
generate modest increases in revascularization rates (22). 
Why does this differential recruitment of low-risk patrents 
into thruLmbolysii *rials occur? Four potential explanations can 
be set aside. Pii restrict& of trial entry to younger indiid- 
uals was specified in many early studies (23-27). but not in 
GUSM) or LATE. Second, trial complexity could favor entry 
of lower-risk patients. However, the r;lagnitude of the age-sex 
selection et&t was comparabIe between GUSTO, which had 
very shuple entry criteria and a 3-page follow-up form, and 
LATE, which had more awnplex ent:y criteria and a M-page 
follow-up form. In the “simplest” of thrombolysis trials, the 
Third International Study of Infarct Smvlval (ISIS-3) (28) with 
very wide eligibility critkris and a one-page follow-up form, 
27% of patients were female, and 26% were aged 70 or more; 
both are disproportionately low relative to the population 
r&ribution of acute myocardial infarction (3). As well in the 
“uncertain indidn” arm of ISIS-3, in whii use of throm- 
hdysis was left to the trial invest@tor. the distributii of age 
andsexwassimiIartothatinathertriakofthmmk+&(2). 
This~thlltthroncbolysistrialparttiptiOiI~ybeIllO~ 
of a &&on factor than eligibility for thro+&& per se. 
Third,shortertimeto treatment by younger and male patients 
has been noted (29-31), but this is aii unIikely explanation for 
~~~~~~,~r~~~~~of~ 
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(Table 2). Fourth, it is unquestionably more difficult to obtain 
informed consent to trial participation from seriously il l pa- 
tients or very elderly patients. However, the distribution of age, 
sex, Killip class and anterior acute myocardial infarction in 
other large-scale thrombolysis trials (18,32) in which informed 
conscr.t was not required was similar to that of GUSTO, where 
written informed consent was needed. 
We suggest that the observed recruitment pattern arises 
from reluctance to use thrombolysis in older and sicker 
patients, reluctance to initiate recruitment of such patients into 
trials, or some combination of the two factors. Restrictive entry 
criteria in the first generation of thrombolysis trials doubtless 
left uncertainty about the net benefits of thrombolysis in older 
pa’ients. Althnugh a recent overview of trial evidence (2) 
inrlicates substa.ltial net benefit from thrombolysis in older 
acute myocardial infarction persons, older patients also sutfer 
more adverse effects from thrombolysis. We speculate that 
ohysicians concerns about cau:.ing harm to older patients are 
heightened in the context of a randomized trial, where the 
thrombolysis treatment decision is left to the play of chance. 
More generally, randomization might act to heighten uncer- 
tainty when managing older or sicker patients whose prognosis 
is already a source of anxiety. 
Survival advantage among trial patients: expIanatIons and 
implications. Age, sex and comorbidity scores were found to 
be independent predictors of improved survival after acute 
myocardial infarction, as wzs coronary revascularization. How- 
ever, even after controlling for these four factors, GUSTO or 
LATE participants had an approximately twofold better 
chance of smvival than nontrial patients ?t the same hospital or 
at external hospitals (Table 4). Do differences in patient 
management or patient characteristics explain this survival 
advantage? 
Monugenzenr parrems. Trial patients who survived to dis- 
charge stayed, on average, ;day less in hospital than nontrial 
patients, but unrecorded dea?zs out of hospital on the next day 
would be exceedingly rare at zl have a trivial effect on the 
results. Treatment with thrombolysii itself could account for a 
I.25fold to 1.33-fold better chance’ of survival (i.e., a 20% to 
25% relative risk reduction) but does not alone explain UK: 
persisting twofold diierences seen. Moreover, the survival 
advantage was comparable in GUSTO, in which all patients 
received thrombolysis, and LATE, where only half received 
thrombolysis. Also, some proportion of nontrial p&ntswould 
inevitably receive thmmbolysis-a factor that would tend to 
reduce the extent of survival advantage att&utabIe solely to 
thmmboiysis use *within trials. Overall pharmacotherapy and 
monitoring of complicatii may also have been better for trial 
patients. However, aspirin use has been shawn to be similar 
inside and outside trials (3334); and although beta-blockers 
also reduce in-hospital mortality (35) we have no information 
on whether they were used more commordy among trial 
patients. In sum, the survival advantage seems too large to be 
rtxplik!abIe by manage-t patterns per se. 
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the survival advantage, we would not expect comparable 
survival advantages for patients in LATE and GUSTO. We 
controlled for age and sex ddferences between trial and 
nontrial patients, so that the impact of this aspect of prefer- 
ential recruitment of lower risk patients should be mitigated. 
The prevalences of anterior acute myocardial infarction in 
GUSID and LATE (42% and 43%, respectively) were similar 
to population-based registries of acute myocardial infarction 
(4); hence infarct location is unliiely to be a contributory 
factor. However, a post hoc analysis of the entire GUSTO data 
bm has shown that, along with age, the three strongest 
predictors of postinfarct 3lhiay mortality (13) are admission 
heart rate, admission systolic blood pressure and admission 
Kilfip class. Because our nontrial patients w’ere characterized 
with administrative rather than clinical trial data, we cannot 
compare trial and nontrial patients with respect to these and 
other prognostic factors We strongly suspect that selection 
bias led to differences in these unmeasured characteristics of 
trial and nontrial patients and that these differences are 
important in understanding the observed survival differences. 
Strengths ad Iknhtl0n.s d study sei&odology. Our 
methods have several advantages Thzse inchuie linkage to 
population-based data with a high sensi5ity and spzcitieity for 
detection of deaths in bspi:al. cx-zrptis across two major 
thrombolysis trials with distinct ehgibitity criteria and interven- 
tion strategies and sample sizes large enough to detect clini- 
cally meaningful effects. As already noted, a key hmitation of 
the study is the lack of clinical detail in the computerized 
hospital discharge abstracts that were used to provide a 
population-based perspective on trial recruitment and 1 ut- 
comes. Two other limitations bear mention. 
First. there is always the polentiai for inconsistency in 
reporting or coding variables across institutions. Mircoding of 
acute myocardial infarction is a reco@ed problem in com- 
puterized discharge abstracts generated by North American 
hospitals (1213). We used longitudinal linkage in our popula- 
tion-based data set to limit the influence of false-positive 
cod& of acute myocardial infarction associated with readmis- 
sions or transfers. However, another recognized source of 
false-positive coding is admission of patients with chest pain to 
“rule out acute myocardial infarction” (1213). We conducted 
a sensitivity analysis (data on requestj excluding patients with 
staysIwthan3d~toscreenoutindividuakinthe”ruleout 
acme myocat&l infarction”categotywho might have unstable 
angina or noueardiac chest pain. The percent of patients 
excluded ranged from 21% to 2.4% across groups, and odds 
ratios for the adjusted survival advantage were undmnged or 
minimally larger. This was expected because trial patients had 
ax&med acute myoc~~M infarction with typical star and 
th net elkct of endudii short-stay patients was to exclude a 
small number of survivors from the nontrial patient groups 
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deaths from acute myocardiil infarction (deaths before 5 
weeks) occur in hospital on the index admission (2.3). Among 
those who survive to day 2, 90% of the short-term improve- 
ment in outcomes with thrombolytii therapy arises within IO 
days of’admission (2). that is, within our typical length of stay. 
However, we do not have other outcomes that may be useful 
indicators of overall quality of care, such as longer-term 
mortality in or GU: of hospital. quality of life, functional status 
and satisfaction with care (3637). 
ReievaneetoiahvPmseareharulcRnfeaJ~Ran- 
domized trials remain the best way to determine if a given 
treatment is efficacious. The rigorous conduct of trials with 
large sample sires can enhance the internal validity of any 
results, but in the cast of thrombol@s for acute myocardial 
infarction, preferential recruitment of lower risk pattents has 
tended to limit the external validity or generalizability of 
individual trial results. Fortunately. so many patients have 
been randomized in thrombolysis trials that combining high- 
risk subgroups from multiple trials through metaanalysis (2) 
now provides statijtical power to confirm that the relative 
reduction in risk of death is comparable (and the absolute 
reduction greater) in the elderly, those with previous acute 
myocardial infarction and those with low systolii blood pres- 
sure. In many other areas of practice, such large numbers of 
randomized patients are unlikely to be available for metaanaty- 
sir Moreover, although it is comrnonplacc to assume that 
patients at higher baseline risk of adverse outcomes will have 
greater net benefit with an eflicacii treatment, this assump 
Cion is not always defensible (38). We accordingly suggest that 
those designing trials should not only consi&r the range of 
absolute event rates and potential net benefits expected for 
varying subgroups of potential enrollees but also explore 
strategies that would explicitly enhance recruitment of repre- 
sentative numbers of patients from hi risk subgnu+. 
As noted eartier, the past failure to recruit h&h tisk patients 
into trials may partly he a result of unwillingness to add the 
uncertainty ofcollsetlt procemes and randomiition to man- 
agement of older, sicker patients Fears of the side effects of 
thrombolysis in such patients may also be a factor. However. a 
cause-and-egect cycle is thereby created. To the extent that 
detitiitive evidence is lacking to prove net benefits for hi-risk 
patients, it becomes harder to promote widespread adopuon of 
such therapies intc routine practice. Thus, it is pernapS not 
surprising that dlrombolytic use in routine ptktice (4X39,40) 
or men within trials of other interventions (41) has mirrored 
thmnhulysis trial recruitment. with preferential u~iliition in 
k4vtiskpatientcWiththeaggregateevidencefromovetvim 
ofmultipkethmmbob&triafsnmuavailabletoshownet 
benefit for high-risk pi&entx (2). it is to be hoped that pmctioe 
panemsWiU~hthefUlure. 
We emphasire, however. that the translation ofctinimd trial 
resultsintopmcticeisamuhifXetedphetxmKMH1.’Ibecom- 
pkxfactotsshaping~behaYiorinbothItMkalid 
pract&remaiarfert&efieMforfuturereseamhAbettu 
oftho5efaetorsanlldinAonniflitiativ&~: 
not only at representative reeruitsnent of patients into 
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randomized trials but also at optimal ditfusion of validated 
innovations such as thrombolytic therapy for acute myocar- 
dial infarction. 
&Is and s&&t of Dr. Paul W. Am&g, do chaired Caoadian . pruhqam in both the GWIU and LATE oiak We extend, with Lk. 
Armmug, oar thks to tbe more &an 3,ooO Canadian patients end the scores 
d physidm and IIUM who participated in these trials. 
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